Sponsor:
MultiValent Biotherapies, Inc.
Code:
NCT07944508
Conditions
Localized Prostate Adenocarcinoma
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MVB-101
Brief summary:
Conditions
Localized Prostate Adenocarcinoma
Study ID
NCT07944508
Start date
Aug 14, 2026
Status verified date
Nov, 2026
Completion date
Mar, 2028
Anticipated
Primary completion date
Dec, 2027
Anticipated
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
60 participants
Anticipated
Allocation
Non randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Part A: MVB-101 1 mg
experimental: Part A: MVB-101 2 mg
experimental: Part A: MVB-101 4 mg
experimental: Part A: MVB-101 8 mg
experimental: Part B: MVB-101 Dose Expansion
Interventions
MVB-101
Primary outcome measure
Central contacts
Locations
Urology Centers of Alabama
Recruiting
Homewood, Alabama, United States, 35209
Contacts
Urology San Antonio
Recruiting
San Antonio, Texas, United States, 78229
Contacts
Sponsor
MultiValent Biotherapies, Inc.
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by MultiValent Biotherapies, Inc. on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.